Valeo Pharma Inc.
VPHIF
Rank in Stocks
#34471
Valeo Pharma Inc. is a Canadian specialty pharmaceutical firm dedicated to... Valeo Pharma Inc. is a Canadian specialty pharmaceutical firm dedicated to sourcing, licensing, and selling a variety of medicinal products, with a primary emphasis on respiratory, specialized, and hospital-grade generic drugs. Its extensive product lineup features prominent asthma medications like Enerzair Breezhaler (a triple-combination LABA/LAMA/ICS) and Atectura Breezhaler (a dual-combination LABA/ICS). The company also offers Redesca, crucial for preventing and treating deep vein thrombosis and pulmonary embolism. For neurological conditions, Valeo markets Onstryv, an add-on treatment for Idiopathic Parkinson's Disease in patients on stable Levodopa, and Benztropine, an anticholinergic for PD. Pain management is addressed with M-Eslon, an extended-release morphine sulfate, while Yondelis targets soft tissue sarcoma. Beyond these, the portfolio includes Hesperco, an immune-supporting bioflavonoid antioxidant; Ametop, a skin anesthetic used before venous procedures; Ethacrynate Sodium, a loop diuretic for high blood pressure and swelling; and Amikacin, an injectable antibiotic. Founded in 2003, Valeo Pharma Inc. is headquartered in Kirkland, Canada.
Share Price
$0.0001
Last synced: 2026-11-10
Market Cap
$9.87K
Change (1 day)
0.00%
Change (1 year)
-66.67%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Valeo Pharma Inc. (VPHIF)
Category
Healthcare
Operating Margin for Valeo Pharma Inc. (VPHIF)
Operating Margin as of November 2026 TTM: -31.96%
According to Valeo Pharma Inc.'s latest financial reports, its current operating margin (TTM) is -31.96%. At the end of 2023 the company had an operating margin of -31.96%.
Operating Margin history for Valeo Pharma Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -31.96% | 0.00% |
| 2023 | -31.96% | -54.77% |
| 2022 | -70.66% | -25.26% |
| 2021 | -94.54% | 62.61% |
| 2020 | -58.14% | 7.87% |
| 2019 | -53.90% | -0.46% |
| 2018 | -54.15% | -73.32% |
| 2017 | -202.95% | -15.84% |
| 2016 | -241.15% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -100.61% |
DE
|
|
| 19.68% | -100.62% |
DE
|
|
| 13.26% | -100.41% |
JP
|
|
| 17.08% | -100.53% |
CH
|
|
| 14.92% | -100.47% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Valeo Pharma Inc.'s operating margin
What is Valeo Pharma Inc.'s operating margin?
Valeo Pharma Inc.'s operating margin is -31.96%, as of Nov 2026.
What was Valeo Pharma Inc.'s operating margin in 2023?
In 2023, Valeo Pharma Inc.'s operating margin was -31.96%, compared with -70.66% in 2022.
How has Valeo Pharma Inc.'s operating margin changed since 2018?
From 2018 to 2023, Valeo Pharma Inc.'s operating margin was highest in 2023 (-31.96%) and lowest in 2021 (-94.54%).
How does Valeo Pharma Inc.'s operating margin compare with similar companies?
Valeo Pharma Inc.'s operating margin (-31.96%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.